FDA Brief

Warning letters Food

FDA warning letter to

Sal Nature LLC/FertilHerb

LowIssued May 20, 2021Posted May 26, 2021Center for Food Safety and Applied Nutrition

FDA and FTC warn Sal Nature/FertilHerb that fertility supplement website claims make it an unapproved drug and misbranded.

What happened

FDA reviewed www.fertilherb.com in March 2021 and found it took orders for “FertilHerb for Women” and made claims that the supplement treats fertility problems, polycystic ovary syndrome (PCOS), irregular menstruation, and miscarriage risk. FDA says those claims make the product a drug intended for disease treatment, and that it is a “new drug” (one needing FDA approval before sale) without approval and misbranded (mislabeled under the law) because it lacks adequate directions for use. FTC reviewed the website in May 2021 and raised concerns that the efficacy claims lack competent and reliable scientific evidence.

What FDA found

  1. Website claims say FertilHerb for Women treats or prevents fertility disorders, PCOS, irregular menstruation, or miscarriage risk, so FDA treats it as a drug.

    Section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]
  2. The product is a new drug because it is not generally recognized as safe and effective for the claimed uses and has no FDA approval.

    Sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. §§ 321(p), 331(d), 355(a)]
  3. The product is misbranded because it lacks adequate directions for laypeople to use it safely for its intended disease uses.

    Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 C.F.R. § 201.5
  4. FTC says the advertising claims may not be supported by competent and reliable scientific evidence as required by the FTC Act.

    FTC Act, 15 U.S.C. § 41 et seq.

What FDA wants

FDA asks the company to notify FDA in writing within 15 working days of receipt of the letter of the specific steps taken to address the violations, including steps to prevent recurrence and related documents; if corrections cannot be completed in that time, the company must explain the delay and when it will finish.

Who should pay attention

  • dietary supplement brands that make fertility or disease-related claims
  • marketers and compliance teams reviewing website claims
  • companies selling supplements without FDA drug approval

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk